First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells
Mohammad Hojjat‐Farsangi(Karolinska University Hospital), Ali Moshfegh(Karolinska University Hospital), Thomas Olin(Kancera (Sweden)), J. Shetye(Karolinska University Hospital), Pedram Kharaziha(Karolinska University Hospital), Erik Olsson(Uppsala University), Anders Österborg(Karolinska University Hospital), Parviz Kokhaei(Arak University of Medical Sciences), Charlotta Löfberg(Kancera (Sweden)), Amir Hossein Daneshmanesh(Karolinska University Hospital), Håkan Mellstedt(Karolinska University Hospital), Lotta Hansson(Karolinska Institutet), Jan Vågberg(Kancera (Sweden)), Fariba Mozaffari(Karolinska University Hospital), Abdul Salam Khan(Karolinska University Hospital), L.-S. Rathje(Karolinska University Hospital), S Byström(Kancera (Sweden)), Johan Schultz(Kancera (Sweden)), Martin Norin(Kancera (Sweden)), Carina Norström(Kancera (Sweden))
Cited by 52
Related Papers
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2010|587
Nanoparticles and targeted drug delivery in cancer therapy
|Immunology Letters|2017|507
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2022|453
The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer
|Biomedicine & Pharmacotherapy|2018|312